Cited by 951Schizophrenia research and treatmentCardiac Health and Mental HealthDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 150 of the 152 references it cites were found in a registry or an index.

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)

De Hert, M., Dekker, J.M., Wood, D., Kahl, K.G., Holt, R.I.G., Möller, H.-J.·2009·European Psychiatry

DOI 10.1016/j.eurpsy.2009.01.005

Open this paper in CoChat — free account

Abstract

People with severe mental illnesses, such as schizophrenia, depression or bipolar disorder, have worse physical health and reduced life expectancy compared to the general population. The excess cardiovascular mortality associated with schizophrenia and bipolar disorder is attributed in part to an increased risk of the modifiable coronary heart disease risk factors; obesity, smoking, diabetes, hypertension and dyslipidaemia. Antipsychotic medication and possibly other psychotropic medication like antidepressants can induce weight gain or worsen other metabolic cardiovascular risk factors. Patients may have limited access to general healthcare with less opportunity for cardiovascular risk screening and prevention than would be expected in a non-psychiatric population. The European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC) published this statement with the aim of improving the care of patients suffering from severe mental illness. The intention is to initiate cooperation and shared care between the different healthcare professionals and to increase the awareness of psychiatrists and primary care physicians caring for patients with severe mental illness to screen and treat cardiovascular risk factors and diabetes.

Integrity signals

Registry

Crossref · 10.1016/j.eurpsy.2009.01.005

Cites

150 of 150 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 retracted

RETRACTED: Obesity and physical activity: A review
Bensimhon, D., Kraus, W. E., & Donahue, M. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.03.005 · Cited by 122
Retracted
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose Tolerance
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“- Document téléchargé le 23/06/2011 par AS OF EUROPEAN diabetes [78,131].”
Background
Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892
2007 Guidelines for the Management of Arterial Hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cífková, R., Fagard, R. H., Germanò, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · Journal of Hypertension · doi:10.1097/hjh.0b013e3281fc975a · Cited by 5,870
European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,865
Self-citation
The Cardiovascular Health Study: design and rationale.
Fried, L. P., Borhani, N. O., Enright, P., Furberg, C. D., Gardin, J. M., Kronmal, R. A., Kuller, L. H., Manolio, T. A., Mittelmark, M. B., Newman, A., et al. (1991) · Annals of Epidemiology · doi:10.1016/1047-2797(91)90005-w · Cited by 3,652
Diagnosis and Classification of diabetes mellitus
Rossi, G. (2014) · Diapedia.org eBooks · doi:10.14496/dia..20 · Cited by 3,212
International Expert Committee report on the role of the A1c assay in the diagnosis of diabetes
The International Expert Committee (2009) · Diabetes Care · doi:10.2337/dc09-9033 · Cited by 3,185
Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy.
Rozanski, A., Blumenthal, J. A., & Kaplan, J. (1999) · Circulation · doi:10.1161/01.cir.99.16.2192 · Cited by 2,846
2007 Guidelines for the management of arterial hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., Cifkova, R., Fagard, R., Germano, G., Grassi, G. M., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm236 · Cited by 2,410
Antipsychotic-induced weight gain: a comprehensive research synthesis
Allison, D. B., Mentore, J. L., Heo, M., Chandler, L. P., Cappelleri, J. C., Infante, M. C., & Weiden, P. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.11.1686 · Cited by 2,382
Standards of Medical Care in Diabetes—2009
American Diabetes Association (2009) · Diabetes Care · doi:10.2337/dc09-s013 · Cited by 2,167
A Systematic Review of Mortality in Schizophrenia: Is the Differential Mortality Gap Worsening Over Time?
Saha, S., Chant, D., & McGrath, J. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.10.1123 · Cited by 2,065
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Impaired Fasting Glucose and Impaired Glucose Tolerance
Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc07-9920 · Cited by 1,396
Second-Generation (Atypical) Antipsychotics and Metabolic Effects
Newcomer, J. W. (2005) · CNS Drugs · doi:10.2165/00023210-200519001-00001 · Cited by 1,352
Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states.
(2006) · Europe PMC (PubMed Central) · Cited by 1,299
Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes
Boehm, G., Racoosin, J. A., LAUGHREN, T. P., & Katz, R. G. (2004) · Diabetes Care · doi:10.2337/diacare.27.8.2088-a · Cited by 1,204
Atypical antipsychotic drugs and the risk of sudden cardiac death
Ray, W. A., Chung, C. P., Murray, K. T., Hall, K., & Stein, C. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806994 · Cited by 1,194
Lipid screening and cardiovascular health in childhood
Daniels, S. R., Greer, F. R., & and the Committee on Nutrition (2008) · Pediatrics · doi:10.1542/peds.2008-1349 · Cited by 1,178
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial
Kahn, R. S., Fleischhacker, W. W., Boter, H., Davidson, M., Vergouwe, Y., Keet, I. P., Gheorghe, M. D., Rybakowski, J. K., Galderisi, S., Libiger, J., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60486-9 · Cited by 1,088
Causes of the excess mortality of schizophrenia
Brown, S., Inskip, H., & Barraclough, B. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.177.3.212 · Cited by 1,087
Schizophrenia and increased risks of cardiovascular disease
Hennekens, C. H., Hennekens, A. R., Hollar, D., & Casey, D. E. (2005) · American Heart Journal · doi:10.1016/j.ahj.2005.02.007 · Cited by 1,070
Examining a Bidirectional Association Between Depressive Symptoms and Diabetes
Golden, S. H. (2008) · JAMA · doi:10.1001/jama.299.23.2751 · Cited by 916
Mortality of patients with mood disorders: follow-up over 34–38 years
Angst, F., Stassen, H. H., Clayton, P. J., & Angst, J. (2002) · Journal of Affective Disorders · doi:10.1016/s0165-0327(01)00377-9 · Cited by 881
Excess mortality of schizophrenia: A meta-analysis
Brown, S. (1997) · British Journal of Psychiatry · doi:10.1192/bjp.171.6.502 · Cited by 869
Depression and obesity
Stunkard, A. J., Faith, M. S., & Allison, K. C. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00608-5 · Cited by 841
Physical Health Monitoring of Patients With Schizophrenia
Marder, S. R., Essock, S. M., Miller, A. L., Buchanan, R. W., Casey, D. E., Davis, J. M., Kane, J. M., Lieberman, J. A., Schooler, N. R., Covell, N. H., et al. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.8.1334 · Cited by 812
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 718
European guidelines on cardiovascular disease prevention in clinical practice: Executive summary
Graham, I. M. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2007.08.024 · Cited by 716
Mortality and causes of death in schizophrenia in Stockholm County, Sweden
Ösby, U., Correia, N., Brandt, L., Ekbom, A., & Sparén, P. (2000) · Schizophrenia Research · doi:10.1016/s0920-9964(99)00191-7 · Cited by 679 · cited 2×
“This excess mortality is not only caused by increased suicide; people with SMI have an increased risk of mortality associated with physical illness, with the commonest cause of death being cardiovascular disease (CVD) [15,16,17,25,26,65,82,103,104, 106,107].”
Background
Depression, Psychotropic Medication, and Risk of Myocardial Infarction: Prospective Data From the Baltimore ECA Follow-up
Pratt, L. A., Ford, D. E., Crum, R. M., Armenian, H. K., Gallo, J. J., & Eaton, W. W. (1996) · Circulation · doi:10.1161/01.cir.94.12.3123 · Cited by 643
The role of stress and the hypothalamic–pituitary–adrenal axis in the pathogenesis of the metabolic syndrome: neuro-endocrine and target tissue-related causes
Chrousos, G. P. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801278 · Cited by 637
Metabolic syndrome in people with schizophrenia: a review
DE HERT, M., SCHREURS, V., VANCAMPFORT, D., & VAN WINKEL, R. (2009) · World Psychiatry · doi:10.1002/j.2051-5545.2009.tb00199.x · Cited by 634
Physical illness and schizophrenia: a review of the literature
Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2007.01095.x · Cited by 633
Depression and Risk for Onset of Type II Diabetes: A prospective population-based study
Eaton, W. W., Armenian, H. K., Gallo, J. J., Pratt, L., & Ford, D. E. (1996) · Diabetes Care · doi:10.2337/diacare.19.10.1097 · Cited by 611
Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database
Osborn, D. P. J., Levy, G., Nazareth, I., Petersen, I., Islam, A., & King, M. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.242 · Cited by 608
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline
Nasrallah, H. A., Meyer, J. M., GOFF, D. C., McEvoy, J. P., Thomas, S., Stroup, T. S., & Lieberman, J. A. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.06.026 · Cited by 563
A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls
Goff, D. C., Sullivan, L. M., McEvoy, J. P., Meyer, J. M., Nasrallah, H. A., Daumit, G. L., Lamberti, S., D'Agostino, R. B., Stroup, T. S., Davis, S., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.010 · Cited by 528
Exercise interventions for smoking cessation
USSHER, M. H., Taylor, A. H., & Faulkner, G. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002295.pub5 · Cited by 526
Adverse Effects of Atypical Antipsychotics
Haddad, P. M., & Sharma, S. G. (2007) · CNS Drugs · doi:10.2165/00023210-200721110-00004 · Cited by 468
Effectiveness of Olanzapine, Quetiapine, Risperidone, and Ziprasidone in Patients With Chronic Schizophrenia Following Discontinuation of a Previous Atypical Antipsychotic
Stroup, T. S., Lieberman, J. A., McEvoy, J. P., Swartz, M. S., Thomas, S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., DAVIS, C. E., Severe, J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.4.611 · Cited by 431
Adiposity, Fat Distribution, and Cardiovascular Risk
Peiris, A. N., Sothmann, M. S., Hoffmann, R. G., Hennes, M. I., Wilson, C. R., Gustafson, A. B., & Kissebah, A. H. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-110-11-867 · Cited by 423
Antipsychotic medications: metabolic and cardiovascular risk.
Newcomer, J. W. (2007) · PubMed · Cited by 416
Obesity Among Those with Mental Disorders
Allison, D. B., Newcomer, J. W., Dunn, A. L., Blumenthal, J. A., Fabricatore, A. N., Daumit, G. L., Cope, M. B., Riley, W. T., Vreeland, B., Hibbeln, J. R., et al. (2009) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2008.11.020 · Cited by 403
Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study
Tiihonen, J., Wahlbeck, K., Lönnqvist, J. K., Klaukka, T., Ioannidis, J. P. A., Volavka, J., & Haukka, J. K. (2006) · BMJ · doi:10.1136/bmj.38881.382755.2f · Cited by 389
Lifestyle Intervention and Metformin for Treatment of Antipsychotic-Induced Weight Gain: A Randomized Controlled Trial
Wu, R.-R., Zhao, J.-P., Jin, H., Shao, P., Fang, M.-S., Guo, X.-F., He, Y.-Q., Liu, Y.-J., Chen, J.-D., & Li, L.-H. (2008) · JAMA · doi:10.1001/jama.2007.56-b · Cited by 366
Depression and the Metabolic Syndrome in Young Adults: Findings From the Third National Health and Nutrition Examination Survey
Kinder, L. S., Carnethon, M. R., Palaniappan, L. P., King, A. C., & Fortmann, S. P. (2004) · Psychosomatic Medicine · doi:10.1097/01.psy.0000124755.91880.f4 · Cited by 365
The American Association of Clinical Endocrinologists Medical Guidelines for the Management of Diabetes Mellitus: the Aace System of Intensive Diabetes Self-Management—2002 Update
Feld, S. (2002) · Endocrine Practice · doi:10.4158/ep.8.s1.40 · Cited by 359
Our Reviewers
Gelenberg, A. J. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0101 · Cited by 355
Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients
Zimmermann, U., Kraus, T., Himmerich, H., Schuld, A., & Pollmächer, T. (2003) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00018-9 · Cited by 349
Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia
Thakore, J. H., Mann, J. N., Vlahos, I., Martin, A. J., & Reznek, R. H. (2002) · International Journal of Obesity · doi:10.1038/sj.ijo.0801840 · Cited by 331
Comorbid Somatic Illnesses in Patients With Severe Mental Disorders: Clinical, Policy, and Research Challenges
Fleishhacker, W. W., Cetkovich-Bakmas, M., De Hert, M., Hennekens, C. H., Lambert, M., Leucht, S., Maj, M., McIntyre, R. S., Naber, D., Newcomer, J. W., et al. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0401 · Cited by 328
The Comorbidity of Diabetes Mellitus and Depression
Katon, W. J. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.008 · Cited by 323
Non-pharmacological management of antipsychotic-induced weight gain: Systematic review and meta-analysis of randomised controlled trials
Álvarez‐Jiménez, M., Hetrick, S. E., González‐Blanch, C., Gleeson, J., & McGorry, P. D. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.042853 · Cited by 315
Elevated Frequency of Diabetes Mellitus in Hospitalized Manic-Depressive Patients
Cassidy, F., Ahearn, E. P., & Carroll, B. J. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.9.1417 · Cited by 300
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1
Meyer, J. M., Davis, V. G., GOFF, D. C., McEvoy, J. P., Nasrallah, H. A., Thomas, S., Rosenheck, R. A., Daumit, G. L., Hsiao, J., Swartz, M. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2007.12.487 · Cited by 286
First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: Systematic review and meta-analysis
Smith, M. J., Hopkins, D., Peveler, R., Holt, R. I. G., Woodward, M., & Ismail, K. (2008) · The British Journal of Psychiatry · doi:10.1192/bjp.bp.107.037184 · Cited by 274
Self-citation
Somatic hospital contacts, invasive cardiac procedures, and mortality from heart disease in patients with severe mental disorder
Laursen, T. M., Munk-Olsen, T., Agerbo, E., Gasse, C., & Mortensen, P. B. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.61 · Cited by 271
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Acute treatment of schizophrenia
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Gattaz, W. F., Möller, H., & WFSBP Task Force on Treatment Guide (2005) · The World Journal of Biological Psychiatry · doi:10.1080/15622970510030090 · Cited by 271
Self-citation
Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980–1998
Lawrence, D. M., D'Arcy, C., Holman, J., Jablensky, A. V., & Hobbs, M. S. T. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.1.31 · Cited by 269
Metabolic side effects of antipsychotic medication
Tschoner, A., Engl, J., Laimer, M. W., Kaser, S., Rettenbacher, M. A., Fleischhacker, W. W., Patsch, J. R., & Ebenbichler, C. F. (2007) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2007.01416.x · Cited by 265
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
Stahl, S. M., Mignon, L., & Meyer, J. M. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01334.x · Cited by 258
The metabolic syndrome and schizophrenia
Meyer, J. M., & Stahl, S. M. (2008) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01317.x · Cited by 250
Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: A retrospective chart review
Binder, M. D., Schreurs, V., Sweers, K., Eyck, D. V., Hanssens, L., Šinko, S., Wampers, M., Scheen, A. J., Peuskens, J., & van Winkel, R. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.01.028 · Cited by 247
Elevated depression symptoms, antidepressant medicine use, and risk of developing diabetes during the diabetes prevention program
Rubin, R. R., Ma, Y., Marrero, D. G., Peyrot, M., Barrett-Connor, E. L., Kahn, S. E., Haffner, S. M., Price, D. W., Knowler, W. C., & for the Diabetes Prevention Program Research Group (2008) · Diabetes Care · doi:10.2337/dc07-1827 · Cited by 242
Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent?
Simon, V., van Winkel, R., & Binder, M. D. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08r04392 · Cited by 239
Interventions to reduce weight gain in schizophrenia
Faulkner, G., Cohn, T. A., & Remington, G. J. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005148.pub2 · Cited by 226
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study
Daumit, G. L., Goff, D. C., Meyer, J. M., Davis, V. G., Nasrallah, H. A., McEvoy, J. P., Rosenheck, R., Davis, S. M., Hsiao, J. K., Stroup, T. S., et al. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.07.006 · Cited by 223
Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study
Osby, U. (2000) · BMJ · doi:10.1136/bmj.321.7259.483 · Cited by 220
Metabolic Syndrome and the Risk of Coronary Heart Disease in 367 Patients Treated With Second-Generation Antipsychotic Drugs
Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0408 · Cited by 216
Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study.
Hert, M. A. F. D., van Winkel, R., Eyck, D. V., Hanssens, L. S., Wampers, M., Scheen, A. J., & Peuskens, J. (2006) · Clinical Practice and Epidemiology in Mental Health · doi:10.1186/1745-0179-2-14 · Cited by 209
Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: Systematic review and metaanalysis
Osborn, D. P., Wright, C. A., Levy, G., King, M. B., Deo, R., & Nazareth, I. (2008) · BMC Psychiatry · doi:10.1186/1471-244x-8-84 · Cited by 208
Bipolar disorder and diabetes mellitus: epidemiology, etiology, and treatment implications
Mcintyre, R., Konarski, J., Misener, V., & Kennedy, S. (2005) · Annals of Clinical Psychiatry · doi:10.1080/10401230590932380 · Cited by 203
The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms
McIntyre, R. S., Soczynska, J. K., Konarski, J. Z., & Kennedy, S. H. (2005) · Expert Opinion on Drug Safety · doi:10.1517/14740338.5.1.157 · Cited by 203
Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950–2005
Capasso, R., Lineberry, T. W., Bostwick, J. M., Decker, P. A., & Sauver, J. L. S. (2007) · Schizophrenia Research · doi:10.1016/j.schres.2007.10.005 · Cited by 202
Depression and Ischemic Heart Disease Mortality: Evidence From the EPIC-Norfolk United Kingdom Prospective Cohort Study
Surtees, P. G., Wainwright, N. W. J., Luben, R., Wareham, N. J., Bingham, S. A., & Khaw, K. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07061018 · Cited by 199
Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study
Bobes, J., Arango, C., Aranda, P., Carmena, R., García-García, M., & Rejas, J. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.09.025 · Cited by 195
Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
Kumra, S., Oberstar, J. V., Sikich, L., Findling, R. L., McClellan, J. M., Vinogradov, S., & Schulz, S. C. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm109 · Cited by 189
Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder
van Winkel, R., Binder, M. D., Eyck, D. V., Hanssens, L., Wampers, M., Scheen, A. J., & Peuskens, J. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2007.00520.x · Cited by 185
Prevalence and Predictors of Lipid and Glucose Monitoring in Commercially Insured Patients Treated With Second-Generation Antipsychotic Agents
Haupt, D. W., Rosenblatt, L. C., Kim, E., Baker, R. A., Whitehead, R. E., & Newcomer, J. W. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08030383 · Cited by 180
Abnormal glucose metabolism in patients treated with antipsychotics
Scheen, A. J., & Hert, M. A. F. D. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.01.003 · Cited by 177
Metabolic Monitoring for Patients Treated with Antipsychotic Medications
Cohn, T. A., & Sernyak, M. J. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100804 · Cited by 176
Weight gain
Berken, G. H., Weinstein, D. O., & Stern, W. C. (1984) · Journal of Affective Disorders · doi:10.1016/0165-0327(84)90031-4 · Cited by 170
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
Barnett, A. H., Mackin, P., Chaudhry, I. B., Farooqi, A., Gadsby, R., Heald, A. H., Hill, J., Millar, H. L., Peveler, R., Rees, A., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107075509 · Cited by 168
Longitudinal Association Between Depressive Symptoms and Incident Type 2 Diabetes Mellitus in Older Adults
Carnethon, M. R. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.8.802 · Cited by 167
Increased intra-abdominal fat deposition in patients with major depressive illness as measured by computed tomography
Thakore, J. H., Richards, P. J., Reznek, R. H., Martin, A., & Dinan, T. G. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(97)85394-2 · Cited by 167
Obesity, serious mental illness and antipsychotic drugs
Holt, R. I. G., & Peveler, R. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01038.x · Cited by 166
Self-citation
Association Between Early and Rapid Weight Gain and Change in Weight Over One Year of Olanzapine Therapy in Patients with Schizophrenia and Related Disorders
Kinon, B. J., Kaiser, C. J., Ahmed, S., Rotelli, M. D., & Kollack‐Walker, S. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000161501.65890.22 · Cited by 164
Schizophrenia and weight management: a systematic review of interventions to control weight
Faulkner, G., Soundy, A., & Lloyd, K. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.2003.00218.x · Cited by 163
Equally increased risk for metabolic syndrome in patients with bipolar disorder and schizophrenia treated with second‐generation antipsychotics
Correll, C. U., Frederickson, A. M., Kane, J. M., & Manu, P. (2008) · Bipolar Disorders · doi:10.1111/j.1399-5618.2008.00625.x · Cited by 158
Improving medical care for persons with serious mental illness: challenges and solutions.
Druss, B. G. (2007) · PubMed · Cited by 157
Sexual Dysfunction in Patients Treated With Atypical Antipsychotics
Meyer, J. M. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0908e26 · Cited by 154
Effects of typical and atypical antipsychotics on glucose–insulin homeostasis and lipid metabolism in first-episode schizophrenia
Wu, R., Zhao, J., Liu, Z., Zhai, J., Guo, X., Guo, W., & Tang, J. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0384-5 · Cited by 148
History of Depression Increases Risk of Type 2 Diabetes in Younger Adults
Brown, L. C., Majumdar, S. R., Newman, S. C., & Johnson, J. A. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1063 · Cited by 143
The threshold for diagnosing impaired fasting glucose: a position statement by the European Diabetes Epidemiology Group
On behalf of, E. D. E. G., Forouhi, N. G., Balkau, B., Borch-Johnsen, K., Dekker, J., Glumer, C., Qiao, Q., Spijkerman, A., Stolk, R., Tabac, A., et al. (2006) · Diabetologia · doi:10.1007/s00125-006-0189-4 · Cited by 140
Self-citation
Prevalence and correlates of overweight in drug-naïve patients with bipolar disorder
Maina, G., Salvi, V., Vitalucci, A., D’Ambrosio, V., & Bogetto, F. (2008) · Journal of Affective Disorders · doi:10.1016/j.jad.2007.12.233 · Cited by 135
The Atypical Antipsychotic Therapy and Metabolic Issues National Survey
Newcomer, J. W., Nasrallah, H. A., & Loebel, A. D. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000142281.85207.d5 · Cited by 133
Mood disorders: cardiovascular and diabetes comorbidity
Fenton, W. S., & Stover, E. S. (2006) · Current Opinion in Psychiatry · doi:10.1097/01.yco.0000228765.33356.9f · Cited by 131
Challenges in the management of bipolar depression.
Suppes, T. M., Kelly, D. I., & Perla, J. M. (2005) · PubMed · Cited by 127
LITHIUM MAINTENANCE TREATMENT OF MANIC‐MELANCHOLIC PATIENTS: ITS ROLE IN THE DAILY ROUTINE
Bech, P., Vendsborg, P., & Rafaelsen, O. J. (1976) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1976.tb00060.x · Cited by 127
2007 guidelines for the management of arterial hypertension
Mancia, G., Backer, G. D., Dominiczak, A. F., CIFKOVA, R., FAGARD, R., Germano, G., Grassi, G., Heagerty, A. M., KJELDSEN, S., LAURENT, S., et al. (2007) · Ghent University Academic Bibliography (Ghent University) · Cited by 127
Hyperglycemia and Diabetes in Patients With Schizophrenia or Schizoaffective Disorders
Cohen, D., Stolk, R. P., Grobbee, D. E., & Wied, C. C. G. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-1261 · Cited by 115
Cardiovascular Abnormalities in Patients with Major Depressive Disorder
Brown, A. D. H., Barton, D. A., & Lambert, G. W. (2009) · CNS Drugs · doi:10.2165/00023210-200923070-00004 · Cited by 111
Major Changes in Glucose Metabolism, Including New-Onset Diabetes, Within 3 Months After Initiation of or Switch to Atypical Antipsychotic Medication in Patients With Schizophrenia and Schizoaffective Disorder
van Winkel, R., Binder, M. D., Wampers, M., Eyck, D. V., Hanssens, L., Scheen, A. J., & Peuskens, J. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0320 · Cited by 110
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder
Smith, R. C., Lindenmayer, J., Davis, J. M., Cornwell, J. A., Noth, K., Gupta, S., Sershen, H. W., & Lajtha, Á. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.02.001 · Cited by 107
The Hypothalamic-Pituitary-Adrenal System in Depression
Heuser, I. (1998) · Pharmacopsychiatry · doi:10.1055/s-2007-979288 · Cited by 106
Do guidelines for severe mental illness promote physical health and well-being?
Citrome, L., & Yeomans, D. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059505 · Cited by 103
Schizophrenia: who is at risk? Who is a case?
Verdoux, H., & Cougnard‐Grégoire, A. (2006) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000201496.23259.85 · Cited by 102
Clinicians' recognition of the metabolic adverse effects of antipsychotic medications
Buckley, P. F., Miller, D. D., SINGER, B., ARENA, J., & Stirewalt, E. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.04.010 · Cited by 102
Intra-abdominal fat: is it a major factor in developing diabetes and coronary artery disease?
Kissebah, A. H. (1996) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(96)80035-0 · Cited by 99
Diabetes and schizophrenia 2005: are we any closer to understanding the link?
Holt, R. I. G., Bushe, C., & Citrome, L. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105058379 · Cited by 98
Self-citation
A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients
Mackin, P., Bishop, D. R., & Watkinson, H. (2007) · BMC Psychiatry · doi:10.1186/1471-244x-7-28 · Cited by 96
A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: Findings from the CLAMORS study
Arango, C., Bobes, J., Aranda, P., Carmena, R., García-García, M., & Rejas, J. (2008) · Schizophrenia Research · doi:10.1016/j.schres.2008.05.009 · Cited by 93
Screening for Diabetes and Other Metabolic Abnormalities in Patients With Schizophrenia and Schizoaffective Disorder
van Winkel, R., Binder, M. D., Eyck, D. V., Hanssens, L., Hanssens, L., Wampers, M., Scheen, A. J., & Peuskens, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1002 · Cited by 92
Interventions to Reduce Weight Gain in Schizophrenia
Faulkner, G., Cohn, T., & Remington, G. J. (2007) · Schizophrenia Bulletin · doi:10.1093/schbul/sbm022 · Cited by 92
Exercise interventions for smoking cessation
USSHER, M. H., Taylor, A. H., & Faulkner, G. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002295.pub3 · Cited by 91
Pharmacologic and Nonpharmacologic Strategies for Weight Gain and Metabolic Disturbance in Patients Treated with Antipsychotic Medications
Faulkner, G., & Cohn, T. A. (2006) · The Canadian Journal of Psychiatry · doi:10.1177/070674370605100805 · Cited by 89
Balancing Efficacy and Safety in Treatment with Antipsychotics
Correll, C. U. (2007) · CNS Spectrums · doi:10.1017/s1092852900026298 · Cited by 85
Belgian consensus on metabolic problems associated with atypical antipsychotics
Nayer, A. D., Hert, M. D., Scheen, A. J., Gaal, L. V., Peuskens, J., & on behalf of the Consensus Group (2005) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651500510018310 · Cited by 80
Stress and Cardiovascular Disease
Björntorp, P. (2011) · Springer eBooks · doi:10.1007/978-1-84882-419-5 · Cited by 78
[Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry].
Ruiz, J. S., García, J. B., Ruiloba, J. V., Ubago, J. G., & González, M. P. G.-P. (2008) · Actas Españolas de Psiquiatría · Cited by 74
Prevalence of Diabetes Mellitus Among Outpatients With Severe Mental Disorders Receiving Atypical Antipsychotic Drugs
Lamberti, J. S., Crilly, J. F., Maharaj, K., Olson, D. P., Wiener, K., Dvorin, S., Costea, G. O., Bushey, M. P., & Dietz, M. B. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0517 · Cited by 74
Psychiatric Diagnosis as an Independent Risk Factor for Metabolic Disturbances
van Winkel, R., van Os, J., Ćelić, I., Eyck, D. V., Wampers, M., Scheen, A. J., Peuskens, J., & Binder, M. D. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0817 · Cited by 74
Treatment With Rosuvastatin for Severe Dyslipidemia in Patients With Schizophrenia and Schizoaffective Disorder
Binder, M. D., Kalnická, D., van Winkel, R., Wampers, M., Hanssens, L., Eyck, D. V., Scheen, A. J., & Peuskens, J. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1208 · Cited by 66
Visceral Fat Deposition and Insulin Sensitivity in Depressed Women With and Without Comorbid Borderline Personality Disorder
Kahl, K. G., Bester, M., Greggersen, W., Rudolf, S., DIBBELT, L., Stoeckelhuber, B. M., Gehl, H., Sipos, V., Hohagen, F., & Schweiger, U. (2005) · Psychosomatic Medicine · doi:10.1097/01.psy.0000160458.95955.f4 · Cited by 65
Self-citation
Antipsychotic drugs and diabetes—an application of the Austin Bradford Hill criteria
Holt, R. I. G., & Peveler, R. (2006) · Diabetologia · doi:10.1007/s00125-006-0279-3 · Cited by 65
Self-citation
Risk of Treatment-Emergent Diabetes Mellitus in Patients Receiving Antipsychotics
Citrome, L. L., Holt, R. I., Zachry, W. M., Clewell, J. D., Orth, P. A., Karagianis, J. L., & Hoffmann, V. P. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k141 · Cited by 64
Self-citation
Pharmacological treatment of severe dyslipidaemia in patients with schizophrenia.
Hanssens, L., Binder, M. D., Kalnická, D., van Winkel, R., Wampers, M., Eyck, D. V., Scheen, A. J., & Peuskens, J. (2007) · PubMed · doi:10.1097/yic.0b013e3280113d3b · Cited by 57
Screening for the metabolic syndrome in patients receiving antipsychotic treatment: a proposed algorithm
Waterreus, A. J., & Laugharne, J. D. E. (2009) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2009.tb02344.x · Cited by 53
AACE Diabetes Mellitus Clinical Practice Guidelines Task Force
(2007) · Endocrine Practice · doi:10.1016/s1530-891x(20)46419-5 · Cited by 51
Depression, Diabetes, and Glycemic Control in an American Indian Community
Sahota, P. K. C., Knowler, W. C., & Looker, H. C. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0513 · Cited by 49
The Safety of Olanzapine in Adolescents With Schizophrenia or Bipolar I Disorder
Kryzhanovskaya, L. A., Robertson-Plouch, C. K., Xu, W., Carlson, J. L., Merida, K. M., & Dittmann, R. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m03538 · Cited by 43
Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials.
Bushe, C., & Leonard, B. E. (2007) · PubMed · Cited by 43
The acceptability of physical activity programming within a smoking cessation service for individuals with severe mental illness
Faulkner, G., Taylor, A. H., Munro, S., Selby, P. L., & Gee, C. J. (2006) · Patient Education and Counseling · doi:10.1016/j.pec.2006.11.003 · Cited by 41
An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder
Hirschfeld, R. M. A., Eerdekens, M., Kalali, A. H., Canuso, C. M., Khan, A. A., Karcher, K., & Palumbo, J. (2005) · International Clinical Psychopharmacology · doi:10.1097/01.yic.0000177017.41558.fc · Cited by 40
Blood Glucose and Schizophrenia
Bushe, C., & Leonard, B. E. (2007) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v68n1107 · Cited by 38
Management of Atypical Antipsychotic Drug‐Induced Weight Gain: Focus on Metformin
Miller, L. J. (2009) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.29.6.725 · Cited by 37
[Prevention and treatment of somatic complications arising from the use of antipsychotics].
Cahn, W., Ramlal, D., Bruggeman, R., de Haan, L., Scheepers, F. E., van Soest, M. M., Assies, J., & Slooff, C. J. (2008) · PubMed · Cited by 32
Stress and Cardiovascular Disease
Revankar, B. S. R., Reddy, K. R., & Chinnaiyan, K. M. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_20 · Cited by 32
Physical illness and schizophrenia
Kumar, C. T. S. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.184.6.541 · Cited by 28
P.3.c.071 Epidemiological study for the evaluation of metabolic disorders in patients with schizophrenia: The METEOR Study
Hert, M. D., Falissard, B., Mauri, M., Shaw, K. M., & Wetterling, T. (2008) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(08)70655-2 · Cited by 23
Brain-Performance Correlates of Working Memory Retrieval in Schizophrenia: A Cognitive Modeling Approach
Brown, G. G., McCarthy, G., Bischoff‐Grethe, A., Özyurt, İ. B., Greve, D. N., Potkin, S. G., Turner, J. A., Notestine, R. J., Calhoun, V. D., Ford, J. M., et al. (2008) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn149 · Cited by 23
Atypical Antipsychotic-Induced Diabetes Mellitus in Child and Adolescent Psychiatry
Cohen, D., & Huinink, S. A. T. B. (2007) · CNS Drugs · doi:10.2165/00023210-200721120-00006 · Cited by 16
COST-EFFECTIVENESS OF SCREENING FOR DIABETES IN A COHORT OFPATIENTS WITH SCHIZOPHRENIA
Bruggeman, R., Schorr, S. G., van der Elst, K. C. M., Postma, M. J., & Taxis, K. (2008) · Schizophrenia Research · doi:10.1016/s0920-9964(08)70491-2 · Cited by 11
Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome
Holt, R. I. G. (2006) · The British Journal of Diabetes · doi:10.1177/14746514060060050301 · Cited by 11
Self-citation
IS IT APPROPRIATE TO USE CARDIOVASCULARRISK SCORES IN PATIENTS WITH PSYCHOTIC DISORDERS?
Taxis, K., Schorr, S. G., Fouchier, M., Slooff, C. J., & Bruggeman, R. (2008) · Schizophrenia Research · doi:10.1016/s0920-9964(08)70515-2 · Cited by 10
Guidelines for biological Treatment of Schizophrenia, : Part 1: Acute Treatment of Schizophrenia and Part 2: Long-term Treatment of Schizophrenia
Falkai, P., Wobrock, T., Lieberman, J. A., Glenthoj, B. Y., Wf, G., Möller, H., Altamura, A., Andreasen, N. C., Barnes, T., Beckmann, H., et al. (2005) · The World Journal of Biological Psychiatry · Cited by 5
Self-citation

Research works printed but not linked: 8

10.1176/ajp.2006.163.4.611 · DOI
Scheen, 2008, Traitement neuroleptique et troubles metabolic, Med Mal Metabol, 2, 593
Correll, 2008, Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents, J Clin Psychiatry, 69, 26
Citrome, 2007, Risk-Benefit Analysis of Available Treatments for Schizophrenia, Psychiatric Times, 1, 27
2008, Clinical Practice Guidelines for the prevention and management of diabetes in Canada, Can J Diabetes, 32, S1
Casey, 2004, Antipsychotic-Induced Weight Gain and Metabolic Abnormalities: Implications for Increased Mortality in Patients With Schizophrenia, J Clin Psychiatry, 65, 4
Henderson, 2005, Schizophrenia and comorbid metabolic disorders, J Clin Psychiatry, 66, 11
Nicol, 2009, Preliminary results of the MEAC study: metabolic effects of antipsychotics in children, Schizophr Bull, 35, 32

Sorted by citations

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Self-citation
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
DE HERT, M., CORRELL, C. U., BOBES, J., CETKOVICH‐BAKMAS, M., COHEN, D., ASAI, I., DETRAUX, J., GAUTAM, S., MÖLLER, H., NDETEI, D. M., et al. (2011) · World Psychiatry · doi:10.1002/j.2051-5545.2011.tb00014.x · Cited by 2,488
Self-citation
Priority actions for the non-communicable disease crisis
Beaglehole, R., Bonita, R., Horton, R., Adams, C., Alleyne, G., Asaria, P., Baugh, V., Bekedam, H., Billo, N., Casswell, S., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60393-0 · Cited by 1,615
The Lancet Psychiatry Commission: a blueprint for protecting physical health in people with mental illness
Firth, J., Siddiqi, N., Koyanagi, A., Siskind, D., Rosenbaum, S., Galletly, C., Allan, S., Caneo, C., Carney, R., Carvalho, A. F., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30132-4 · Cited by 1,531
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Self-citation

See all 951

Authors: De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J.
Affiliations: KU Leuven (BE)
Imperial College London (GB)
Medizinische Hochschule Hannover (DE)
University of Southampton (GB)
Ludwig-Maximilians-Universität München (DE)
ORCID: Wood, D.
Holt, R.I.G.
Venue: European Psychiatry
Publisher: Cambridge University Press (CUP)
Published: 2009-09
Volume: 24
Issue: 6
Pages: 412-424
ISSN: 0924-9338 (ISSN-L)
1778-3585
DOI: 10.1016/j.eurpsy.2009.01.005
OpenAlex: W2154493342
Cited by: 951
References: 152
Citations by year: 2026: 27 · 2025: 32 · 2024: 37 · 2023: 61 · 2022: 42 · 2021: 64 · 2020: 59 · 2019: 62 · 2018: 46 · 2017: 44 · 2016: 69 · 2015: 63 · 2014: 71 · 2013: 66 · 2012: 65
FWCI: 42.54
Type: journal article
Language: en
Open access: closed
Licence: www.cambridge.org/core/terms (unspecified, 3880 d)
Locations: European Psychiatry (publishedVersion)
PubMed (publishedVersion)
Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
Lirias (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Funders: Bristol-Myers Squibb
European Society of Cardiology
European Association for the Study of Diabetes
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: severe mental illness, cardiovascular disease, diabetes mellitus, schizophrenia, bipolar disorder, depression, cardiovascular risk factors, antipsychotic-induced weight gain, psychotropic drugs, cardiovascular risk screening, cardiovascular disease prevention, shared care, life expectancy, coronary artery disease
MeSH terms: Bipolar Disorder, Cardiovascular Diseases, Cause of Death, Cross-Sectional Studies, Major Depressive Disorder, Diabetes Mellitus, Follow-Up Studies, Humans, Mass Screening, Obesity, Psychotic Disorders, Psychotropic Drugs, Risk Factors, Schizophrenia, Societies, Medical, Comorbidity, Practice Guidelines as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks